"ADAM17 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A disintegrin and metalloproteinase domain-containing protein that cleaves the membrane-bound precursor of TUMOR NECROSIS FACTOR-ALPHA to its mature form. It cleaves several other CELL SURFACE PROTEINS, including INTERLEUKIN-1 RECEPTOR TYPE II; TRANSFORMING GROWTH FACTOR ALPHA; L-SELECTIN; MUCIN-1; and AMYLOID BETA-PROTEIN PRECURSOR. It can also function as an activator of the Notch signaling pathway by mediating the cleavage of NOTCH RECEPTORS.
| Descriptor ID |
D000072198
|
| MeSH Number(s) |
D08.811.277.656.675.374.102.375 D09.400.430.500.375 D12.776.395.033.375
|
| Concept/Terms |
ADAM17 Protein- ADAM17 Protein
- TACE (Enzyme)
- TNF-alpha Converting Enzyme
- TNF alpha Converting Enzyme
- Tumor Necrosis Factor Alpha Convertase
- ADAM-17
- Tumor Necrosis Factor-alpha Converting Enzyme
- Tumor Necrosis Factor alpha Converting Enzyme
- TNF-alpha Convertase
- Convertase, TNF-alpha
- TNF alpha Convertase
- CD156b Antigen
- Antigen, CD156b
- ADAM-17 Protein
- ADAM 17 Protein
- Disintegrin and Metalloproteinase Domain-Containing Protein 17
- Disintegrin and Metalloproteinase Domain Containing Protein 17
- TACA (Enzyme)
- Tumor Necrosis Factor-alpha Convertase
|
Below are MeSH descriptors whose meaning is more general than "ADAM17 Protein".
Below are MeSH descriptors whose meaning is more specific than "ADAM17 Protein".
This graph shows the total number of publications written about "ADAM17 Protein" by people in this website by year, and whether "ADAM17 Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
| 2020 | 1 | 5 | 6 |
| 2021 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "ADAM17 Protein" by people in Profiles.
-
MicroRNA-28-3p inhibits angiotensin-converting enzyme 2 ectodomain shedding in 293T cells treated with the spike protein of severe acute respiratory syndrome coronavirus 2 by targeting A disintegrin and metalloproteinase 17. Int J Mol Med. 2021 Oct; 48(4).
-
A model for COVID-19-induced dysregulation of ACE2 shedding by ADAM17. Biochem Biophys Res Commun. 2021 10 08; 573:158-163.
-
Which ones, when and why should renin-angiotensin system inhibitors work against COVID-19? Adv Biol Regul. 2021 08; 81:100820.
-
Severe COVID-19 Patients Show an Increase in Soluble TNFR1 and ADAM17, with a Relationship to Mortality. Int J Mol Sci. 2021 Aug 05; 22(16).
-
Anti-TNF-a agents Modulate SARS-CoV-2 Receptors and Increase the Risk of Infection Through Notch-1 Signaling. Front Immunol. 2021; 12:641295.
-
Effects of SARS-CoV-2 on Cardiovascular System: The Dual Role of Angiotensin-Converting Enzyme 2 (ACE2) as the Virus Receptor and Homeostasis Regulator-Review. Int J Mol Sci. 2021 Apr 26; 22(9).
-
Pulmonary, cardiac and renal distribution of ACE2, furin, TMPRSS2 and ADAM17 in rats with heart failure: Potential implication for COVID-19 disease. J Cell Mol Med. 2021 04; 25(8):3840-3855.
-
A pressor dose of angiotensin II has no influence on the angiotensin-converting enzyme 2 and other molecules associated with SARS-CoV-2 infection in mice. FASEB J. 2021 03; 35(3):e21419.
-
Upregulation of the Renin-Angiotensin System Pathways and SARS-CoV-2 Infection: The Rationale for the Administration of Zinc-Chelating Agents in COVID-19 Patients. Cells. 2021 02 27; 10(3).
-
Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19. Clin Sci (Lond). 2021 02 12; 135(3):465-481.